Therapy » Intra-articular introduction of hyaluronic acid in patients with early osteoarthritis

Intra-articular introduction of hyaluronic acid in patients with early osteoarthritis

DOI: https://dx.doi.org/10.18565/therapy.2025.1.177-182

Gaydukova I.Z., Mazurov V.I.
1) I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia, Saint Petersburg; 2) V.A. Nasonova Clinical Rheumatology Hospital No. 25, Saint Petersburg

Abstract. Osteoarthritis (OA) is one of the most common rheumatic diseases, in which low-grade inflammation plays a significant role, affecting all structural elements of the joint and leading to the degradation of its tissues. To reduce inflammation with nonsteroidal anti-inflammatory drugs (NSAIDs) can be difficult for a number of objective reasons, the most important of which are poor penetration of systemic NSAIDs into avascular joint tissues and limited possibilities of using these drugs in patients with comorbid diseases. In this regard, the most promising way of reducing inflammation (pain) and the rate of joint tissue degeneration is intra-articular introduction of hyaluronic acid (HA), which, according to international and Russian sources, is characterized by efficacy in a large number of patients with OA, including those having initial stages of pathological process. At the same time, HA administered locally demonstrates high safety comparatively to drugs used orally. Modified structure of HA and modern buffers for intra-articular introduction provide a higher concentration of the medicine in the joint, helping to provide a long-term analgesic and structure-modifying effect. Intra-articular administration of HA can be an effective therapeutic measure both at an advanced and early stage of OA of the knee joint.

Keywords: intra-articular introduction, systemic nonsteroidal anti-inflammatory drugs, hyaluronic acid, comorbid conditions, osteoarthritis

Read entire article

Literature

1. Галушко Е.А., Насонов Е.Л. Распространенность ревматических заболеваний в России. Альманах клинической медицины. 2018; 46(1): 32–39. (Galushko E.A., Nasonov E.L. Prevalence of rheumatic diseases in Russia. Al’manakh klinicheskoy meditsiny = Almanac of Clinical Medicine. 2018; 46(1): 32–39 (In Russ.)).

https://doi.org/10.18786/2072-0505-2018-46-1-32-39. EDN: YVSHGT.

2. Wesseling J., Welsing P.M.J., Bierma-Zeinstra S.M.A. et al. Impact of self-reported comorbidity on physical and mental health status in early symptomatic osteoarthritis: The CHECK (Cohort Hip and Cohort Knee) study. Rheumatology (Oxford). 2013; 52(1): 180–88.

https://doi.org/10.1093/rheumatology/kes288. PMID: 23093723.

3. Pihl K., Roos E.M., Taylor R.S. et al. Associations between comorbidities and immediate and one-year outcomes following supervised exercise therapy and patient education – a cohort study of 24,513 individuals with knee or hip osteoarthritis. Osteoarthritis Cartilage. 2021; 29(1): 39–49.

https://doi.org/10.1016/j.joca.2020.11.001. PMID: 33220446. PMCID: PMC7116561.

4. Гайдукова И.З., Мазуров В.И., Инамова О.В. Магнитно-резонансная томография как дополнительный инструмент выбора терапии при лечении остеоартрита. РМЖ. 2020; 28(11): 43–48. (Gaydukova I.Z., Mazurov V.I., Inamova O.V. Magnetic resonance imaging as an additional tool for treatment tactics for osteoarthritis. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2020; 28(11): 43–48 (In Russ.)). EDN: MPIXUR.

5. Bruyere O., Honvo G., Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337–50.

https://doi.org/10.1016/j. semarthrit.2019.04.008. PMID: 31126594.

6. Bannuru R.R., Osani M.C., Vaysbrot E.E. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019; 27(11): 1578–89.

https://doi.org/10.1016/j.joca.2019.06.011. PMID: 31278997.

7. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. с соавт. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56(S1): 1–29. (Karateev A.E., Nasonov E.L., Ivashkin V.T. et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchcno-practicheskaya revmatologiya = Rheumatology Science and Practice. 2018; 56(S1): 1–29 (In Russ.)).

https://doi.org/10.14412/rjtao20180. EDN: PCPKRP.

8. Ревматология. Фармакотерапия без ошибок: руководство для врачей. Под ред. В.И. Мазурова, О.М. Лесняк. М.: Е-ното. 2017; 528 с. (Rheumatology. Pharmacotherapy without errors: A guide for doctors. Ed. by Mazurov V.I., Lesnyak O.M. Moscow: E-noto. 2017; 528 pp. (In Russ.)). ISBN: 978-5-906023-17-9.

9. Гайдукова И.З., Мазуров В.И. Эффективность нестероидных противовоспалительных препаратов. Журнал неврологии и психиатрии им. C.C. Корсакова. 2019; 119(5): 134–140. (Gaydukova I.Z., Mazurov V.I. The efficacy of non-sreroidal anti-inflammatory drugs. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019; 119(5): 134–140 (In Russ.)).

https://doi.org/10.17116/jnevro2019119051134. EDN: GOPVPD.

10. Лила А.М., Алексеева Л.И., Бабаева А.Р. с соавт. Возможности фармакологического лечения остеоартрита: фокус на симптоматические медленнодействующие препараты (SYSADOA) и индивидуальные особенности пациента. Резолюция международного совещания экспертов. Современная ревматология. 2019; 13(4): 143–147. (Lila A.M., Alekseeva L.I., Babaeva A.R. et al. Pharmacological treatment options for osteoarthritis: Focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting. Modern Rheumatology Journal. 2019; 13(4): 143–147 (In Russ.)).

https://doi.org/10.14412/1996-7012-2019-4-143-147. EDN: MBAXCN.

11. Лазебник Л.Б., Голованова Е.В., Алексеенко С.А. с соавт. Рекомендации по профилактике и лечению эзофаго-гастро-энтеро-колопатий, индуцированных нестероидными противовоспалительными препаратами. Экспериментальная и клиническая гастроэнтерология. 2018; (3): 4–18. (Lazebnik L.B., Golovanova E.V., Alekseenko S.A. et al. Recommendations for the prevention and treatment of esophago-gastro-entero-colopathy induced by nonsteroidal antiinflammatory drugs “NSAID”. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2018; (3): 4–18 (In Russ.)). EDN: XUWZUL.

12. Raeissadat S.A., Hosseini P.G., Bahrami M.H. et al. The comparison effects of intra-articular injection of Platelet Rich Plasma (PRP), Plasma Rich in Growth Factor (PRGF), Hyaluronic Acid (HA), and ozone in knee osteoarthritis; a one year randomized clinical trial. BMC Musculoskelet Disord. 2021; 22(1): 134.

https://doi.org/10.1186/s12891-021-04017-x. PMID: 33536010. PMCID: PMC7860007.

13. Tjandra K.C., Novriansyah R., Sudiasa I.N.S. et al. Modified Mesenchymal stem cell, platelet-rich plasma, and hyaluronic acid intervention in early stage osteoarthritis: A systematic review, meta-analysis, and meta-regression of arthroscopic-guided intra-articular approaches. PLoS One. 2024; 19(3): e0295876.

https://doi.org/10.1371/journal.pone.0295876. PMID: 38457479. PMCID: PMC10923406.

14. Zhang C., Lu Y., Huang Y. Clinical efficacy of cell-free fat extract and its effects on bone marrow edema in patients with early to mid-stage knee osteoarthritis: A clinical trial in comparison with hyaluronic acid. J Orthop Surg Res. 2025; 20(1): 153.

https://doi.org/10.1186/s13018-025-05543-3. PMID: 39924508. PMCID: PMC11809086.

15. Jin W.-S., Yin L.-X., Sun H.-Q. et al. Mesenchymal stem cells injection is more effective than hyaluronic acid injection in the treatment of knee osteoarthritis with similar safety: A systematic review and meta-analysis. Arthroscopy. 2025; 41(2): 318–32.

https://doi.org/10.1016/j.arthro.2024.07.027. PMID: 39154667.

16. Tschopp M., Pfirrmann C.W.A., Fucentese S.F. et al. A randomized trial of intra-articular injection therapy for knee osteoarthritis. Invest Radiol. 2023; 58(5): 355–62.

https://doi.org/10.1097/RLI.0000000000000942. PMID: 36728848. PMCID: PMC10090303.

17. Conrozier T. Is the addition of a polyol to hyaluronic acid a significant advance in the treatment of osteoarthritis? Curr Rheumatol Rev. 2018; 14(3): 226–30.

https://doi.org/10.2174/1573397113666170710115558. PMID: 28699498.

18. Rapp C., Boudif F., Bourgoin C. et al. A cross-sectional study of factors predicting the duration of the efficacy of viscosupplementation in knee osteoarthritis. J Clin Med. 2024; 13(7): 1949.

https://doi.org/10.3390/jcm13071949. PMID: 38610715. PMCID: PMC11012299.

19. Pereira T.V., Saadat P., Bobos P. et al. Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis. Osteoarthritis Cartilage. 2025; 33(2): 207–17.

https://doi.org/10.1016/j.joca.2024.08.014. PMID: 39265924.

20. Гайдукова И.З., Волонцевича А., Макеева О.А., Максимова О.В. Русскоязычный перевод и адаптация опросника по оценке 4-летнего риска появления симптоматического остеоартрита коленных суставов. РМЖ. 2024; (8): 21–25. (Gaydukova I.Z., Volontsevicha А., Makeeva O.A., Maksimova O.V. Russian translation and adaptation of the questionnaire for assessing the 4-year risk of symptomatic knee osteoarthritis incidence. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2024; (8): 21–25 (In Russ.)). EDN: IQIUYW.

About the Autors

Inna Z. Gaydukova, MD, Dr. Sci. (Medicine), deputy director of the Research Institute of Rheumatology, professor of the Department of therapy, rheumatology, examination of temporary disability and quality of medical care with a course in hematology and transfusiology named after E.E. Eichwald of I.I. Mechnikov North-West State Medical University of the Ministry of Healthcare of Russia, rheumatologist at V.A. Nasonova Clinical Rheumatology Hospital No. 25. Address: 191015, Saint Petersburg, 41 Kirochnaya St.
E-mail: ubp1976@list.ru
ORCID: https://orcid.org/0000-0003-3500-7256. Scopus Author ID: 55237525900. eLibrary SPIN: 3083-7996
Vadim I. Mazurov, MD, Dr. Sci. (Medicine), professor, academician of RAS, vice president of RSMSIM, principal scientific advisor and director of the Research Institute of Rheumatology, head of the Department of therapy, rheumatology, examination of temporary disability and quality of medical care with a course in hematology and transfusiology named after E.E. Eichwald of I.I. Mechnikov North-West State Medical University of the Ministry of Healthcare of Russia, head of Autoimmune center of V.A. Nasonova Clinical Rheumatology Hospital No. 25, chief freelance specialist – rheumatologist of the Healthcare Committee of the Government of Saint Petersburg, Honored Worker of Science of the Russian Federation. Address: 191015, Saint Petersburg, 41 Kirochnaya St.
E-mail: maz.nwgmu@yandex.ru
ORCID: https://orcid.org/0000-0002-0797-2051. Scopus Author ID: 16936315400. eLibrary SPIN: 6823-5482

Intra-articular introduction of hyaluronic acid in patients with early osteoarthritis

Literature

About the Autors

Similar Articles